Among the fusion proteins, the FGF21R x GCGR x GLP-1R triple-agonist DR10624 by Zhejiang Doer and the GCGR x GIPR x GLP-1R triple-agonist MWN-101 by Shanghai Minwei are in Phase 2 clinical trials
One major area of concern was dosing and formulation variability
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, Roth J (2023) Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Genome Instab Dis2025 Mar
Both semaglutide GLP-1 and Zepbound are highly effective prescription medications approved for weight management, but individual results may vary